Journal Menu

Issues

Journal of Pharmacy Research
ISSN NO: 0974-6943
The Journal of Pharmacy Research is an online Journal, publishing of correct version and document can be modified when, we/or author get comments from any readers. The journal is devoted to the promotion of Pharmaceutical sciences and related disciplines (including Pharmacy, medical, Biotech, Botany, organic and medicinal chemistry,  Nursing, Paramedical, prescription etc  fields).
Scopus Indexed (link http://www.scimagojr.com/journalsearch.php?q=21100325431&tip=sid&clean=0) 

Journal Metrics for this Journal of Pharmacy Research (Source ID: 21100325431): 2015(SNIP) Source Normalized Impact Per Paper : 0.575; SCImago Journal Rank (SJR):0.787; Impact Per Publication : 0.789 CiteScore 2016: 0.93(Top level : Life Science)

Year SJR Cites per document Year Value
2014 0.607 Cites / Doc. (4 years) 2014 0.607
2015 0.787 Cites / Doc. (4 years) 2015 0.789
2016 0.926 Cites / Doc. (4 years) 2016 0.926
    Cites / Doc. (3 years) 2014 0.607
    Cites / Doc. (3 years) 2015 0.789
    Cites / Doc. (2 years) 2014 0.607
    Cites / Doc. (2 years) 2015 0.789
2016   Cites / Doc. (4 years) 2016 0.926
Cites Year Value
External Cites per document 2014 0.607
External Cites per document 2015 0.789
External Cites per document 2016 0.926
Cites per document 2014 0.607
Cites per document 2015 0.789
Cites per document 2016 0.926

Manuscripts Published

Journal: Journal of Pharmacy Research , Volume: 6, Issue: 4.
Article Id: JPRS-PHDRS-00001293
Title: Evaluation of phytochemical and pharmacological aspects of Holarrhena antidysenterica (Wall.): A comprehensive review
Category: Pharmacognosy and Herbal Drugs related study
Section: Review Article
Country: India
View Article

Medicinal plants are generating an ever-increasing amount of interest due to the effectiveness, low cost and minimal side-effects associated with drugs derived from them. Holarrhena antidysenterica (syn. H. pubescens) WALL., belonging to the family Apocynaceae, is commended for the medicinal applications of its stem bark, leaves and seeds in Ayurveda. During the past century, studies on the phytochemical and pharmacological nature of the plant have yielded important results regarding the chemical constituents present and have also verified the traditionally claimed properties associated with the plant viz. analgesic, antibacterial, anti-diarrhoeal, anti-amoebic, anti-inflammatory and anti-haemorrhoidal activities. Moreover, recently some other properties have also been discovered viz. antimalarial, anti-diabetic, anti-oxidant, anti-urolithic, anti-mutagenic, CNS-stimulating, Angiotensin-converting-enzyme inhibitory and acetylcholinesterase inhibitory activity. This review discusses the findings of studies on the aforementioned properties of the plant in detail and 68 alkaloids isolated from various parts of plant to justify its widespread use in the treatment of a variety of diseases and suggests future lines of research.

Journal: Journal of Pharmacy Research , Volume: 6, Issue: 4.
Article Id: JPRS-PB-00001291
Title: Molecular identification of amylase producing Bacillus subtilis and detection of optimal conditions
Category: Pharmaceutical Biotechnology
Section: Research Article
Country: India
View Article

Background: Amylase is of great significance in industrial applications like pharmaceutical, food, textile and paper industries. These enzymes represent approximately 25e33% of the world enzyme market. Methods: Potential amylase producing bacterial strains were isolated using SAM from sago industries waste site samples and optimized for different parameters. Results and diccussion: The maximum amylase production (538 U/ml) was achieved when the temperature was around 32 C at pH 7 by the strain SSII2. The production of amylase was found to enhance when hydrolyzed sago starch was added as a sole carbon source, yeast extract as a nitrogen source and cysteine as an amino acid. After optimizing, the isolates scale up studies were carried out in 5 L fermentor with sago starch waste as a sole carbon source. The production of the enzyme reached 2.72 mg/L after 12 h. After partial purification the concentration of alpha amylase was found to be 54.54 mg/L. The maximum amylase enzyme activity was obtained at the beginning of the stationary growth phase. Conclusion: The isolate was identified as Bacillus subtilis after 16S rDNA sequencing and it proved to be a potent amylase producing strain, which can be further used for potential applications in various biotechnological and industrial processes.

Journal: Journal of Pharmacy Research , Volume: 6, Issue: 4.
Article Id: JPRS-PB-00001290
Title: A randomized, open-label, prospective, multicenter phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections
Category: Pharmaceutical Biotechnology
Section: Research Article
Country: India
View Article

Background: Lower respiratory tract infections (LTRIs) and urinary tract infections (UTIs) are the leading causes of death world-wide. Treatment of these infections require the use of antibiotics with enhanced activity against a broad spectrum of respiratory and urinary pathogens. This study was designed to study clinical and bacteriological efficacy as well as tolerability of ceftiaxone þ disodium edtate þ sulbactam (the novel Antibiotic Adjuvant Entity; Elores) in adult patients in the treatment of lower respiratory tract infections (LRTIs) and urinary tract infections (UTIs). Methods: A randomized, open-label, multicenter study was conducted on 297 patients which included 204 in UTIs and 93 in LRTIs. A total of 148 patients were there in Elores group with 102 cases of UTIs and 46 LRTIs; 149 in ceftriaxone group with 102 cases of UTIs and 47 LRTIs. The patients received 3e10 days of treatment with Elores 3.0 g twice daily and ceftriaxone 2.0 g twice daily in two divided doses. Results and discussion: Clinical cure rates in ITT (Intend to treat) populations of Elores were 83.33% (85/102), 91.30% (42/46) in the UTIs and LRTIs, respectively, and 34.31% (35/102), 31.91% (15/47) in the ceftriaxone group for UTIs and LRTIs, respectively. The corresponding bacterial eradication rates were 95% (57/60) and 97.05% (33/34) for Elores in the UTIs and LRTIs, respectively and 80.64% (50/62) and 71.42% (10/14) for ceftriaxone in the UTIs and LRTIs, respectively. Adverse reaction were observed in 20.59% (21/102) and 15.22% (7/46) in Elores groups of UTIs and LRTIs, respectively and 36.27% (37/102) and 31.91% (14/47) in ceftriaxone groups of UTIs and LRTIs, respectively. Conclusions: Results obtained in the present study, together with microbiological evaluation data suggest that Elores is more effective and safe antibacterial agent for the treatment of LRTIs and UTIs infections

Journal: Journal of Pharmacy Research , Volume: 6, Issue: 4.
Article Id: JPRS-P'Col-00001292
Title: Amorphous solid dispersion method for improving oral bioavailability of poorly water-soluble drugs
Category: Pharmacology
Section: Review Article
Country: India
View Article

Amorphous solid dispersions are one of the most promising strategies to improve the oral bioavailability of sparingly water-soluble drugs. Drug particle size reduction improved the drug wettability and bioavailability significantly. Poorly soluble drugs may benefit from formulation approaches that overcome poor solubility and dissolution rate limited bioavailability. The solubility of a compound in the amorphous form is higher than the more stable crystalline form because the Gibbs free energy is higher. In addition, glasses or amorphous forms are kinetically trapped high energy disordered materials that lack the periodicity of crystals but behave mechanically as solids. Lipophilic molecules, especially those belonging to the biopharmaceutics classification system (BCS) class II and IV, dissolve slowly, like incomplete release from the dosage form, poor bioavailability, increased food effect, and high inter-patient variability. Hence, several formulation approaches can be taken to improve the solubility and dissolution of poorly water-soluble compounds, such as formulating the API in an amorphous form. Amorphous solid dispersions of poorly water-soluble drugs with water-soluble carriers have been reduced the incidence of these problems and enhanced dissolution. This review is mainly focus on advantages, methods of preparation, and characterization of the amorphous solid dispersion.